Thilo Schroeder - Jul 22, 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Director
Signature
/s/ Darren DeStefano, Attorney-in-Fact
Stock symbol
RVMD
Transactions as of
Jul 22, 2022
Transactions value $
$5,000,000
Form type
4
Date filed
7/26/2022, 05:12 PM
Previous filing
Mar 29, 2022
Next filing
Mar 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Purchase $5M +250K +25.74% $20.00 1.22M Jul 22, 2022 By Nextech Crossover I SCSP F1
holding RVMD Common Stock 2.67M Jul 22, 2022 By Nextech V Oncology S.C.S., SICAV-SIF F2
holding RVMD Common Stock 300K Jul 22, 2022 By Nextech VI Oncology SCSp F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F2 Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3 Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.